Rate My Professor Michael Jones

Conjoint Professor Michael Jones serves as an Honorary Professor in the School of Medicine and Public Health within the College of Health, Medicine and Wellbeing at the University of Newcastle. He holds a Bachelor of Science, Bachelor of Engineering with Honours, Bachelor of Medicine and Bachelor of Surgery from the Australian National University, a Master of Public Health and Tropical Medicine, and a Doctor of Philosophy in Medicine from the University of Newcastle, where his doctoral research focused on emerging imaging techniques in radiation oncology. Jones completed his specialist training in radiation oncology at Calvary Mater Newcastle and Chris O’Brien Lifehouse, achieving Fellowship of the Royal Australian and New Zealand College of Radiologists in 2016. He undertook a clinical research fellowship at the Princess Margaret Cancer Centre in Toronto, Canada, concentrating on prostate cancer, gastrointestinal cancers, and lymphoma. Currently, he practices as a radiation oncologist at Icon Cancer Centre Hobart and serves as Director of Radiation Oncology at the WP Holman Clinic, Royal Hobart Hospital. Additionally, he holds an appointment as Clinical Associate Professor in the Tasmanian School of Medicine at the University of Tasmania. His clinical expertise encompasses head and neck cancers, skin malignancies, urological and gynaecological cancers, as well as palliative radiation therapy.

Professor Jones maintains a strong commitment to clinical research, having secured several competitive research grants and serving as principal investigator for multiple active clinical trials in Hobart. He has published in leading international radiation oncology journals, including works on multiparametric MRI as an outcome predictor for anal canal cancer treated with chemoradiotherapy (2015), FDG-PET parameters predicting recurrence in anal cancer, diffusion-weighted magnetic resonance imaging as an early surrogate biomarker of anal cancer response to chemoradiation (2024), and prospective multi-centre trials of multi-parametric MRI. He is a member of the executive committee of the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG), contributing to advancements in prostate cancer management. His conjoint appointment at the University of Newcastle underscores his ongoing ties to the institution through prior training and research.